Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Ian Hamilton-Craig, Karam Kostner, David Colquhoun, Stanley Woodhouse

    Research output: Contribution to journalArticle

    31 Citations (Scopus)

    Abstract

    High-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or heFH. These studies have shown the combination to be both effective and safe in the short to medium term. Recently, short-term ezetimibe therapy has also been shown to be effective and safe in combination with statin therapy for children and adolescents with heFH. Effective statin-ezetimibe combination therapy is capable of achieving near-normal lipid profles in heFH patients, with expected improvement in risk for cardiovascular disease (CVD) and improved life expectancy resulting predominantly from reduction in levels of low-density lipoprotein cholesterol. There are few data to support a pleiotropic action of ezetimibe with regard to CVD beneft, unlike therapy with statins. No serious and unexpected clinical adverse effects of combination statin-ezetimibe therapy have emerged till date, although data are limited in children and adolescents, for whom longer-term studies are required. Recent data suggesting possible proatherogenic effects of ezetimibe require confrmation. One large long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to determine the Efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever be performed in patients with FH.

    Original languageEnglish
    Pages (from-to)1023-1037
    Number of pages15
    JournalVascular Health and Risk Management
    Volume6
    Issue number1
    DOIs
    Publication statusPublished - 2010

    Keywords

    • Combination therapy
    • Ezetimibe
    • Familial hypercholesterolemia
    • Low-density lipoprotein cholesterol
    • Statin

    Fingerprint Dive into the research topics of 'Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia'. Together they form a unique fingerprint.

  • Cite this